HEALTH TECHNOLOGY

Trukera™ Medical Launches New ScoutPro™ Osmolarity System

Trukera Medical | September 13, 2022 | Read time : 02:00 min

Trukera™ Medical

Trukera™ Medical last week announced a corporate rebranding to reflect thea company’s expanded vision and strategic growth plans targeting broader unmet needs in corneal health. Trukera Medical unveiled the first product under the new company name, the ScoutPro™ Osmolarity System. Designed to help advance corneal health decisions for today’s busy eye care practices, ScoutPro is the first and only portable osmometer in the U.S.

The ScoutPro Osmolarity System is an exciting technology developed around the evolving needs of today’s eye care professionals. Premium cataract and refractive practices are now the fastest growing adopters of osmolarity testing, given the prevalence of hyperosmolarity in their patient demographics and the risk it poses to compromising corneal cell health and driving refractive instability. More than ever, these practices require patient care solutions that can seamlessly adapt into established operational models, not the other way around, to deliver a premium patient experience, efficiency of care, and minimize staff time and disruptions. We’re proud to bring a solution to market addressing these needs, and to help more practices objectively identify and manage such a critical component to patient’s corneal health and refractive outcomes.”

Adam Szaronos, Trukera Medical CEO

The ScoutPro Osmolarity System brings together nanoliter volume sample collection and analysis in a single portable device. Users can now bring laboratory testing to patients anywhere in the practice to quickly test and provide objective results in the palm of their hand. The system is built upon the company’s established accuracy trusted in over 24 million tests globally to date, with an industry-leading precision.

“Toxic hyperosmolarity damages sensitive corneal nerves and may cause refractive instability. As cornea and cataract/refractive specialists, we are cognizant of the importance of this to our surgical outcomes and the overall health of our patients’ eyes. ScoutPro gives us the ability to precisely determine osmolarity quickly and easily, without disrupting patient flow,” said Dr. Lisa Nijm, Chief Medical Advisor for Ophthalmology at Trukera Medical and Corneal Surgeon at Warrenville Eye Care and LASIK Center in Illinois.

The ScoutPro Osmolarity System is now available for pre-order in the U.S. and will be commercially launched at the upcoming World Cornea Congress and the American Academy of Ophthalmology later this month. 

About Trukera Medical
Trukera Medical is a global leader in developing and marketing comprehensive corneal health technologies. The company introduced tear osmolarity testing to eye care with its flagship device, the TearLab Osmolarity System, which has been used over 24 million times worldwide. Trukera Medical’s expanding portfolio includes ScoutPro, the first and only portable osmolarity system in the U.S. The company’s dedicated focus is improving corneal health, both as a primary goal and in preparation for surgery. 

Spotlight

Recently there is a frightening trend in teens turning to plastic surgery in an attempt to avoid bullying.

Spotlight

Recently there is a frightening trend in teens turning to plastic surgery in an attempt to avoid bullying.

Related News

FUTURE OF HEALTHCARE

Medimap Partners with Winnipeg Regional Health Authority To Improve Emergency Room Wait Times

Medimap | November 25, 2022

Medimap is pleased to announce it has signed a strategic partnership with the Winnipeg Regional Health Authority to improve patient care and reduce emergency room wait times. The new partnership will make use of Medimap's powerful software technology and its partnerships with a large network of medical clinics in the Winnipeg area by directing Manitobans with low acuity needs to local walk-in clinics. This will help improve Manitobans' access to care by diverting patients with low acuity needs to local medical services that have the capacity to see them, thereby reducing wait times at emergency rooms across the city. "Our new partnership with the Winnipeg Regional Health Authority is a win-win for both patients and the overall healthcare system. Not only will our platform help patients with low acuity needs find the care they need, when they need it, it will also reduce wait times at emergency rooms across the city," Medimap CEO Thomas Jankowski. The partnership means the WRHA will be able to show wait time information at walk-in clinics across the Winnipeg area on hospital screens and its website. The information will allow patients to make informed decisions about where they can get timely access to care. Triage staff will also have immediate access to this information, allowing them to redirect low acuity cases to other healthcare resources. "Every month, approximately 40 percent of people who visit a Winnipeg Urgent Care Centre or emergency department could receive the health care they need, often sooner, through a family doctor or walk-in clinic," said Mike Nader, President and CEO of the Winnipeg Regional Health Authority. "By partnering with Medimap, our goal is to help Manitobans get the timely care they need while reducing the burden on our hospital system. Public-private partnerships like this will help to unlock many of the problems present in our healthcare system." Every month over 250,000 Canadians rely on Medimap as their means of finding same-day, non-urgent access to care. Its software gives clinics the ability to communicate changes in operating hours, or when they are at capacity and also provides the ability for patients to join a waitlist or book an appointment. Patients can quickly check the Medimap website before they travel to a clinic, reducing the length of time they have to wait to see a doctor. Patients can also book appointments with allied health professionals such as physiotherapists, chiropractors, optometrists, mental health services and more. About Medimap Medimap's platform is used by a network of more than 4,200 practices, pharmacies, and walk-in clinics across the country and has helped more than 12 million Canadians find the care they need when they need it. Medimap's platform also provides patients the ability to book appointments with allied health professionals such as physiotherapists, chiropractors, optometrists, mental health services, and more. Not only does this help patients receive timely care, it also helps the healthcare system divert people away from emergency rooms to primary care services that are better suited to their needs, including virtual appointments. About Winnipeg Regional Health Authority The WRHA serves residents of the city of Winnipeg, as well as the northern community of Churchill and the rural municipalities of East and West St. Paul, representing a total population of more than 750,000. The WRHA also provides healthcare support and specialty referral services to nearly half a million Manitobans who live beyond these boundaries, as well as residents of northwestern Ontario and Nunavut, who often require the services and expertise available within the WRHA.

Read More

HEALTH TECHNOLOGY

Biobeat joins Innovators' Network at American Heart Association Center for Health Technology & Innovation

Biobeat | September 07, 2022

Biobeat, a company focused on remote patient monitoring platforms with artificial intelligence analysis capability, has joined the American Heart Association Center for Health Technology & Innovation's (the Center) Innovators' Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions. The Innovators' Network is a consortium that connects entrepreneurs, providers, researchers and payers. Innovators' Network members also have access to the Association's digital guidelines, recommendations, and best-in-class science as they develop digital healthcare technologies. Members collaborate with the Center in different ways, including the building of models for clinical outcome studies, lowering the significant cost of developing those studies independently, helping connect the science to technology, and providing evidence that a digital platform improves healthcare outcomes – a key concern for providers and payers. "The Center aims to advance the rapid, efficient, and effective development of healthcare technology," said Robert A. Harrington, M.D., FAHA, past president of the American Heart Association (2019-2020), volunteer chair of the American Heart Association's Health Tech Advisory Group for the Center and Arthur L. Bloomfield professor and chair department of medicine, Stanford University. "Joining the Innovators' Network gives members the opportunity to leverage the consortium and work toward broadening and deepening their engagement in this arena." "Biobeat is excited to join the Innovators' Network. It will provide unique access to the Association's research and others innovating in this space, helping us to achieve our goals of improving cardiovascular health and helping health care providers." Arik Eisenkraft, MD, VP Clinical and Regulation at Biobeat About Biobeat Biobeat joins the Innovators' Network bringing with them the Biobeat solution, the first cuffless blood pressure measurement tool to receive FDA clearance. Biobeat leverages health-related artificial intelligence and med-tech capabilities to collect and analyze patient data with a suite of optical-based sensor monitors and machine learning data platforms focused on actionable insights. Wireless sensors worn on the wrist or chest allow remote patient monitoring for blood pressure and multiple physiological parameters. Patient health data is viewed by participating medical staff via Biobeat's secure HIPAA and GDPR compliant cloud-based patient management platform. The platform includes an automated real-time early warning score system that incorporates advanced artificial intelligence algorithms to provide alerts on patient health status. These capabilities are centered on supporting medical teams in providing tailored patient care such as adjustment of therapeutics and early prevention of specific disease exacerbations. The company anticipates that compliance with easy-to-wear cuffless health sensor solutions will help healthcare professionals engage in timely, proactive care for hypertension patients.

Read More

HEALTH TECHNOLOGY

Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial

Novartis Pharma AG | September 19, 2022

Sandoz, a global leader in off-patent medicines, announces further progress on its biosimilar pipeline, with the release of positive results from the integrated ROSALIA Phase I/III clinical trial study for its proposed biosimilar denosumab. “Biosimilars have the opportunity to create a substantial positive impact on patient access and healthcare systems sustainability. Therefore, this important milestone means that we are one step closer to giving individuals living with osteoporosis access to a more affordable, biosimilar version of this critical medicine, which may help to change the course of their disease.” Florian Bieber, Global Head of Development, Sandoz Biopharmaceuticals Denosumab is indicated for treating a variety of conditions, including osteoporosis in postmenopausal women, in men at increased risk of fractures, treatment-induced bone loss, prevention of skeletal related complications in cancer that has spread to the bone, and giant cell tumor of the bone2,3,4,5. The results from the integrated Phase I/III study confirm the biosimilar matches the reference medicine in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in the respective indications; and contributes to demonstration of similarity, which is the basis for use in all indications. Approximately 500 million men and women worldwide may be affected by osteoporosis1, which causes 8.9 million fractures annually – or one fracture every three seconds1. By 2050, hip fractures are projected to increase by 240% in women and 310% in men compared to 19901. The results come soon after Sandoz confirmed acceptance of license applications for two other proposed biosimilars. In July 2022, the application for the first-of-a-kind multiple sclerosis proposed biosimilar natalizumab was accepted for review by the US Food and Drug Administration (FDA) and European Medicines Agency. In June 2022, the EMA and FDA accepted for review Sandoz applications for the high-concentration formulation 100 mg/mL (HCF) of its biosimilar adalimumab. Sandoz biosimilars help patients, in areas including immunology, oncology, nephrology, supportive care and endocrinology, access critical and potentially life-changing medicines sustainably and affordably. Sandoz has a leading global portfolio with eight marketed biosimilars and a further 15-plus in various stages of development. About ROSALIA6 In ROSALIA, 527 postmenopausal women with osteoporosis were randomized to receive either biosimilar denosumab or the reference medicine for up to 78 weeks of treatment. Objectives were to demonstrate similar efficacy in terms of change in lumbar spine bone mineral density, as well as similar pharmacokinetics and pharmacodynamics. The global clinical program for biosimilar denosumab was developed in consultation with major regulatory agencies and the results from this clinical study are expected to support regulatory approval. About denosumab Denosumab is a human monoclonal antibody designed to bind to the RANKL protein, an activator of osteoclasts (cells involved in breaking down bone tissue)2. By binding to and inhibiting RANKL, denosumab decreases the production and activity of osteoclasts, resulting in a reduction of bone loss, and subsequently the likelihood of fractures and other serious bone conditions2.

Read More